Profile
Curt W.
Bradshaw was the founder of Solstice Biologics LLC (founded in 2012) and Tallac Therapeutics, Inc. (founded in 2018), where he held the titles of Secretary, Treasurer & Director and President, Chief Scientific Officer & Director, respectively.
He previously worked as a Principal at Abbott Laboratories and Ligand Pharmaceuticals, Inc., and as Chief Scientific Officer at Traversa Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc. (2019-2020).
He also worked at Pfizer Asia as a Principal and is currently the Chief Scientific Officer at NeuBase Therapeutics, Inc. Dr. Bradshaw holds a doctorate degree from Texas A&M University.
Former positions of Curt Bradshaw
| Companies | Position | End |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/11/2020 |
Tallac Therapeutics, Inc.
 Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | Founder | 01/01/2019 |
Solstice Biologics LLC
 Solstice Biologics LLC Pharmaceuticals: MajorHealth Technology Solstice Biologics LLC develops nucleic acid therapeutics. It specializes in the development of small, cell-permeable RNAi pro-drugs. The company was founded by Steven Dowdy and Curt W. Bradshaw in 2012 and is headquartered in San Diego, CA. | Founder | 01/01/2018 |
Traversa Therapeutics, Inc.
 Traversa Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma. The Company was founded in La Jolla, California in mid-2006, and has secured worldwide exclusive licenses to intellectual property developed during the past five years by Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego relating to siRNA delivery technology and induction of RNA Interference (RNAi). | Chief Tech/Sci/R&D Officer | 19/12/2012 |
| NEUBASE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Curt Bradshaw
| Texas A&M University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| NEUBASE THERAPEUTICS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Solstice Biologics LLC
Solstice Biologics LLC Pharmaceuticals: MajorHealth Technology Solstice Biologics LLC develops nucleic acid therapeutics. It specializes in the development of small, cell-permeable RNAi pro-drugs. The company was founded by Steven Dowdy and Curt W. Bradshaw in 2012 and is headquartered in San Diego, CA. | Health Technology |
Traversa Therapeutics, Inc.
Traversa Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma. The Company was founded in La Jolla, California in mid-2006, and has secured worldwide exclusive licenses to intellectual property developed during the past five years by Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego relating to siRNA delivery technology and induction of RNA Interference (RNAi). | Commercial Services |
| Pfizer Asia | |
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | Health Technology |
- Stock Market
- Insiders
- Curt Bradshaw
